Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
Background Amplification of the MYCN oncogene is a molecular hallmark of aggressive neuroblastoma (NB), a childhood cancer of the sympathetic nervous system. There is evidence that MYCN promotes a non-inflamed and T-cell infiltration-poor (‘cold’) tumor microenvironment (TME) by suppressing interfer...
Main Authors: | Michael Hölzel, Johanna A Seier, Julia Reinhardt, Kritika Saraf, Susanna S Ng, Julian P Layer, Dillon Corvino, Kristina Althoff, Frank A Giordano, Alexander Schramm, Matthias Fischer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-05-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/5/e001335.full |
Similar Items
-
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
by: Julian P. Layer, et al.
Published: (2017-06-01) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
by: Maged Zeineldin, et al.
Published: (2020-02-01) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
by: Yan Su, et al.
Published: (2020-11-01) -
MYCN Function in Neuroblastoma Development
by: Jörg Otte, et al.
Published: (2021-01-01) -
Analysis of the MYCN amplicon in neuroblastoma
by: Kenyon, Rebecca Margaret
Published: (1996)